---
title: "GlucoTrack, Inc. (GCTK.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GCTK.US.md"
symbol: "GCTK.US"
name: "GlucoTrack, Inc."
industry: "Health Care Equipment"
datetime: "2026-05-20T12:02:47.109Z"
locales:
  - [en](https://longbridge.com/en/quote/GCTK.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GCTK.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GCTK.US.md)
---

# GlucoTrack, Inc. (GCTK.US)

## Company Overview

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [glucotrack.com](https://glucotrack.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.12 | 55 | - | - | - |
| PB | -2.39 | 155 | 1.13 | 0.61 | 0.46 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GCTK.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GCTK.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GCTK.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GCTK.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**